Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:ARWRNASDAQ:IRONNASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$33.47-0.5%$31.27$23.42▼$62.58$1.94B0.73651,989 shs489,988 shsARWRArrowhead Pharmaceuticals$16.08+0.1%$15.08$9.57▼$30.41$2.22B0.961.54 million shs2.08 million shsIRONDisc Medicine$54.50+0.7%$48.47$30.82▼$68.73$1.89B0.73339,865 shs1.06 million shsTBPHTheravance Biopharma$11.22+4.6%$10.00$7.44▼$11.82$561.01M-0.09268,760 shs1.36 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-0.53%-2.73%+8.56%+10.54%-22.81%ARWRArrowhead Pharmaceuticals+0.06%+4.96%+3.34%+16.35%-38.77%IRONDisc Medicine+0.68%+5.60%+20.79%+4.09%+25.55%TBPHTheravance Biopharma+4.57%+5.55%+22.62%+21.56%+33.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.0239 of 5 stars3.41.00.04.21.80.81.9ARWRArrowhead Pharmaceuticals3.7577 of 5 stars3.42.00.03.42.12.50.0IRONDisc Medicine2.0029 of 5 stars3.51.00.00.02.32.50.0TBPHTheravance Biopharma1.9588 of 5 stars3.30.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6075.08% UpsideARWRArrowhead Pharmaceuticals 2.75Moderate Buy$43.71171.86% UpsideIRONDisc Medicine 3.09Buy$96.7077.43% UpsideTBPHTheravance Biopharma 2.67Moderate Buy$16.6047.95% UpsideCurrent Analyst Ratings BreakdownLatest TBPH, ARWR, IRON, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $25.006/17/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.006/17/2025TBPHTheravance BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$24.006/16/2025IRONDisc MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.006/11/2025IRONDisc MedicineRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$89.005/20/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025ARWRArrowhead PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.005/13/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.005/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M53.11N/AN/A$27.02 per share1.24ARWRArrowhead Pharmaceuticals$3.55M625.53N/AN/A$1.54 per share10.44IRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/ATBPHTheravance Biopharma$64.38M8.71N/AN/A$3.57 per share3.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.242.98N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/A18.91N/A-45.33%-12.49%8/6/2025 (Estimated)IRONDisc Medicine-$109.36M-$3.92N/AN/AN/AN/A-22.61%-21.07%8/6/2025 (Estimated)TBPHTheravance Biopharma-$56.42M-$1.18N/A32.06N/A-89.38%-32.37%-16.48%8/4/2025 (Estimated)Latest TBPH, ARWR, IRON, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/8/2025Q1 2025TBPHTheravance Biopharma-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93ARWRArrowhead Pharmaceuticals0.315.155.15IRONDisc Medicine0.0437.6537.65TBPHTheravance BiopharmaN/A4.774.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AARWRArrowhead Pharmaceuticals62.61%IRONDisc Medicine83.70%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%ARWRArrowhead Pharmaceuticals4.30%IRONDisc Medicine4.24%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableARWRArrowhead Pharmaceuticals400138.10 million132.16 millionOptionableIRONDisc Medicine3034.63 million33.17 millionNot OptionableTBPHTheravance Biopharma35950.00 million46.55 millionOptionableTBPH, ARWR, IRON, and AGIO HeadlinesRecent News About These CompaniesTheravance Biopharma (NASDAQ:TBPH) Trading 5.7% Higher on Analyst UpgradeJune 28 at 2:09 AM | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Trading Up 5.7% on Analyst UpgradeJune 27 at 12:55 PM | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Price Target Raised to $25.00 at BTIG ResearchJune 27 at 11:16 AM | marketbeat.comTBPH Theravance Biopharma, Inc. - Seeking AlphaJune 26 at 9:12 PM | seekingalpha.comTheravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPAJune 26 at 6:00 AM | prnewswire.comTheravance Biopharma (NASDAQ:TBPH) Upgraded by Wall Street Zen to "Buy" RatingJune 21, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives $11.33 Average PT from AnalystsJune 20, 2025 | americanbankingnews.comJones Trading Initiates Coverage on Theravance Biopharma (NASDAQ:TBPH)June 19, 2025 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Shares Gap Up - Still a Buy?June 17, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Hold" from AnalystsJune 17, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from Analysts at Jones TradingJune 17, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average - What's Next?June 17, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)June 9, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 24,000 SharesJune 5, 2025 | marketbeat.comInsider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 24,000 Shares of StockJune 5, 2025 | insidertrades.comPublic Employees Retirement System of Ohio Takes $353,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)June 5, 2025 | marketbeat.comSquarepoint Ops LLC Sells 51,783 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)June 5, 2025 | marketbeat.comTBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock RisesJune 3, 2025 | zacks.comTheravance Biopharma (NASDAQ:TBPH) Hits New 52-Week High - Time to Buy?June 3, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLCJune 3, 2025 | marketbeat.comTheravance Shares Rise Premarket on Sale of Trelegy RoyaltiesJune 2, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Tech Stocks You Can't Miss in This Market CycleBy Gabriel Osorio-Mazilli | June 17, 2025View 3 Tech Stocks You Can't Miss in This Market CycleAeroVironment Will Hit New Highs This Year: Bull Flag ConfirmedBy Thomas Hughes | June 25, 2025View AeroVironment Will Hit New Highs This Year: Bull Flag ConfirmedTBPH, ARWR, IRON, and AGIO Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$33.47 -0.18 (-0.53%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$33.47 0.00 (-0.01%) As of 06/27/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Arrowhead Pharmaceuticals NASDAQ:ARWR$16.08 +0.01 (+0.06%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$16.12 +0.05 (+0.28%) As of 06/27/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Disc Medicine NASDAQ:IRON$54.50 +0.37 (+0.68%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$54.49 -0.01 (-0.02%) As of 06/27/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Theravance Biopharma NASDAQ:TBPH$11.22 +0.49 (+4.57%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$11.41 +0.19 (+1.69%) As of 06/27/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
